{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:20:54Z","timestamp":1772166054696,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1147721"],"award-info":[{"award-number":["OPP1147721"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1147721"],"award-info":[{"award-number":["OPP1147721"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Afghanistan added ROTARIX to the routine national immunization programme in 2018. We aimed to estimate the cost-effectiveness and benefit-risk of ROTARIX and compare its continued use with other rotavirus vaccines that could be used in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a static cohort model with a finely disaggregated age structure (weeks of age\u2009&lt;\u20095 years) to assess the use of ROTARIX (1-dose vial) over a seven-year period (2018\u20132024) in Afghanistan. The primary outcome measure was the discounted cost (2022 US$) per Disability Adjusted Life Year (DALY) averted (from government and societal perspectives) compared to no vaccination. We also calculated the benefit-risk ratio i.e., the number of RVGE deaths prevented per one excess intussusception death. Model inputs were informed by pre- and post-licensure surveillance data, new analyses of household survey data, and updated estimates from the international literature. We ran a separate analysis to compare the potential cost-effectiveness and benefit-risk of ROTARIX (1-dose vial), ROTASIIL (1-dose vial), ROTASIIL (2-dose vial), and ROTAVAC (5-dose vial) over a ten-year period (2025\u20132034). Each product was compared to no rotavirus vaccination and each other. We ran deterministic and probabilistic uncertainty analyses and interpreted our results over a range of cost-effectiveness thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>We estimated that routine use of ROTARIX between 2018 and 2024 has prevented 4,600 RVGE deaths (a 41% reduction), 86,400 hospital admissions, and 1.72\u00a0million RVGE cases. For every 1,493 RVGE deaths prevented by the vaccine, we estimated one potential excess intussusception death. With a heavily reduced vaccine dose cost (due to support from Gavi) the net cost to the Afghanistan government vaccine programme was estimated to be US$ 4.4\u00a0million per year. The cost per DALY averted was US$ 125 (0.25 times the national GDP per capita) when using a Gavi-subsidised vaccine cost and including household costs averted by vaccination. This increased to US$ 471 (0.94 times the national GDP per capita) when incorporating the full vaccine price without Gavi\u2019s subsidy and excluding household costs averted by vaccination. When assuming continued Gavi support over the period 2025\u20132034, the dominant product would be ROTARIX. Without Gavi support, ROTASIIL (2-dose vial) dominates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study supports the sustained use of rotavirus vaccination in Afghanistan. The health benefits of the vaccine greatly exceed the potential risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-025-12885-5","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:11:37Z","timestamp":1751602297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness and benefit-risk of rotavirus vaccination in Afghanistan: a modelling analysis informed by post-licensure surveillance"],"prefix":"10.1186","volume":"25","author":[{"given":"Palwasha","family":"Anwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Debellut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sardar","family":"Parwiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Pecenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"2","key":"12885_CR1","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2214-109X(21)00515-5","volume":"10","author":"D Sharrow","year":"2022","unstructured":"Sharrow D, et al. Global, regional, and National trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by the UN Inter-agency group for child mortality Estimation. Lancet Global Health. 2022;10(2):e195\u2013206.","journal-title":"Lancet Global Health"},{"issue":"9966","key":"12885_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0140-6736(14)61698-6","volume":"385","author":"L Liu","year":"2015","unstructured":"Liu L, et al. Global, regional, and National causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430\u201340.","journal-title":"Lancet"},{"issue":"suppl2","key":"12885_CR3","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1093\/cid\/civ1013","volume":"62","author":"JE Tate","year":"2016","unstructured":"Tate JE, et al. Global, regional, and National estimates of rotavirus mortality in children\u2009<\u20095 years of age, 2000\u20132013. Clin Infect Dis. 2016;62(suppl2):S96\u2013105.","journal-title":"Clin Infect Dis"},{"key":"12885_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijid.2023.10.005","volume":"137","author":"A Clark","year":"2023","unstructured":"Clark A, et al. Estimating the global impact of rotavirus vaccines on child mortality. Int J Infect Dis. 2023;137:90\u20137.","journal-title":"Int J Infect Dis"},{"key":"12885_CR5","unstructured":"WHO. Rotavirus vaccines: WHO position paper-July 2021. Weekly Epidemiological Record. 2021. [Cited 2023 September 29, 2023]. Available from:\u00a0https:\/\/www.who.int\/publications\/i\/item\/WHO-WER9628."},{"key":"12885_CR6","unstructured":"International Vaccine Access Center. Rotavirus Vaccine Introduction. 2023. Available from:\u00a0https:\/\/view-hub.org\/vaccine\/rota?set=current-vaccine-intro-status&group=vaccine-introduction&category=rv."},{"issue":"2","key":"12885_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1473-3099(11)70253-5","volume":"12","author":"JE Tate","year":"2012","unstructured":"Tate JE, et al. 2008 Estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136\u201341.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"12885_CR8","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1016\/S2214-109X(20)30262-X","volume":"8","author":"E Burnett","year":"2020","unstructured":"Burnett E, Parashar UD, Tate JE. Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis. Lancet Global Health. 2020;8(9):e1195\u2013202.","journal-title":"Lancet Global Health"},{"key":"12885_CR9","doi-asserted-by":"crossref","unstructured":"Debellut F, et al. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Glob Health. 2019;7(12):e1664\u201374.","DOI":"10.1016\/S2214-109X(19)30439-5"},{"key":"12885_CR10","unstructured":"UNICEF. Afghanistan introduces rotavirus vaccine to protect infants and young children against severe diarrhea. 2018."},{"issue":"51","key":"12885_CR11","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1016\/j.vaccine.2017.10.058","volume":"36","author":"P Anwari","year":"2018","unstructured":"Anwari P, et al. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Vaccine. 2018;36(51):7769\u201374.","journal-title":"Vaccine"},{"issue":"9","key":"12885_CR12","doi-asserted-by":"publisher","first-page":"e1517","DOI":"10.1016\/S2214-109X(24)00237-7","volume":"12","author":"P Anwari","year":"2024","unstructured":"Anwari P, et al. Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan: a test-negative case-control analysis. Lancet Glob Health. 2024;12(9):e1517\u201325.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"12885_CR13","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.vaccine.2024.02.057","volume":"42","author":"P Anwari","year":"2024","unstructured":"Anwari P, et al. Post-marketing surveillance of intussusception after rotarix administration in Afghanistan, 2018\u20132022. Vaccine. 2024;42(8):2059\u201364.","journal-title":"Vaccine"},{"issue":"48","key":"12885_CR14","doi-asserted-by":"publisher","first-page":"7220","DOI":"10.1016\/j.vaccine.2023.10.042","volume":"41","author":"E Burnett","year":"2023","unstructured":"Burnett E, et al. Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: a self-control case series evaluation. Vaccine. 2023;41(48):7220\u20135.","journal-title":"Vaccine"},{"key":"12885_CR15","unstructured":"Gavi. Gavi-supported rotavirus vaccines profiles to support country decision making. 2023. [Cited 2023 12\/21\/2023]. Available from:\u00a0https:\/\/www.gavi.org\/sites\/default\/files\/programmes-impact\/support\/Gavi-Rotavirus-vaccines-profiles-ENG-February-2023.pdf."},{"issue":"4","key":"12885_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/vaccines11040788","volume":"11","author":"I Mandomando","year":"2023","unstructured":"Mandomando I, et al. Lessons learned and future perspectives for rotavirus vaccines switch in the world health organization, regional office for Africa. Vaccines (Basel). 2023;11(4):788.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"12885_CR17","doi-asserted-by":"publisher","first-page":"e0228506","DOI":"10.1371\/journal.pone.0228506","volume":"15","author":"F Debellut","year":"2020","unstructured":"Debellut F, et al. Introduction of rotavirus vaccination in Palestine: an evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC. PLoS ONE. 2020;15(2):e0228506.","journal-title":"PLoS ONE"},{"key":"12885_CR18","unstructured":"PAHO W. About UNIVAC| Provac Toolkit. [Cited 2023 December 22, 2023]. Available from:\u00a0https:\/\/www.paho.org\/en\/provac-toolkit."},{"issue":"11","key":"12885_CR19","doi-asserted-by":"publisher","first-page":"e1541","DOI":"10.1016\/S2214-109X(19)30412-7","volume":"7","author":"A Clark","year":"2019","unstructured":"Clark A, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Lancet Global Health. 2019;7(11):e1541\u201352.","journal-title":"Lancet Global Health"},{"key":"12885_CR20","unstructured":"WB. The World Bank, GDP per capita (current US$)- Afghanistan. 2024. [Cited 2024 13\/1\/2024]. Available from:\u00a0https:\/\/data.worldbank.org\/indicator\/NY.GDP.MKTP.CD?end=2021&locations=AF&start=2003&view=chart."},{"key":"12885_CR21","unstructured":"UNDP. Two Years in Review: Chaning in Afghan Economy, Households and Cross-cutting Sectors (August 2021 to August 2023). 2023."},{"key":"12885_CR22","unstructured":"WHO. WHO guide for standardization of economic evaluations of immunization programmes, Edition II, Licence: CC BY-NC-SA 3.0 IGO. 2019. [Cited 2022 December 22, 2023]. Available from:\u00a0https:\/\/apps.who.int\/iris\/."},{"issue":"6","key":"12885_CR23","doi-asserted-by":"publisher","first-page":"e6060","DOI":"10.1371\/journal.pone.0006060","volume":"4","author":"J Bilcke","year":"2009","unstructured":"Bilcke J, et al. Estimating the incidence of symptomatic rotavirus infections: A systematic review and Meta-Analysis. PLoS ONE. 2009;4(6):e6060.","journal-title":"PLoS ONE"},{"key":"12885_CR24","volume-title":"Afghanistan multiple Indicator cluster survey 2022-23, survey findings report. Kabul, Afghanistan: united nations children\u2019s fund (UNICEF)","author":"UNICEF","year":"2023","unstructured":"UNICEF. Afghanistan multiple Indicator cluster survey 2022-23, survey findings report. Kabul, Afghanistan: united nations children\u2019s fund (UNICEF). Kabul: UNICEF; 2023."},{"issue":"9875","key":"12885_CR25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(13)60222-6","volume":"381","author":"CLF Walker","year":"2013","unstructured":"Walker CLF, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405\u201316.","journal-title":"Lancet"},{"issue":"51","key":"12885_CR26","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1016\/j.vaccine.2017.06.072","volume":"36","author":"P Anwari","year":"2018","unstructured":"Anwari P, et al. Rotavirus is the leading cause of hospitalizations for severe acute gastroenteritis among Afghan children\u2009<\u20095 years old. Vaccine. 2018;36(51):7765\u20138.","journal-title":"Vaccine"},{"issue":"9","key":"12885_CR27","doi-asserted-by":"publisher","first-page":"e0183392","DOI":"10.1371\/journal.pone.0183392","volume":"12","author":"A Clark","year":"2017","unstructured":"Clark A, et al. Estimating global, regional and National rotavirus deaths in children aged\u2009<\u20095 years: current approaches, new analyses and proposed improvements. PLoS ONE. 2017;12(9):e0183392.","journal-title":"PLoS ONE"},{"key":"12885_CR28","unstructured":"Cost Analysis of Kabul's National Hospitals report, Health Economics and Financing Directorate, editor. Kabul: Ministry of Public Health; 2012."},{"key":"12885_CR29","unstructured":"WUENIC. WHO\/UNICEF Estimates of National Immunisation COverage, 2022 Revision. 2023. [Cited 2023 September 8, 2023]. Available from: https:\/\/worldhealthorg.shinyapps.io\/wuenic-trends-2023\/."},{"issue":"6","key":"12885_CR30","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/cid\/ciz060","volume":"69","author":"M Hasso-Agopsowicz","year":"2019","unstructured":"Hasso-Agopsowicz M, et al. Global review of the age distribution of rotavirus disease in children aged\u2009<\u20095 years before the introduction of rotavirus vaccination. Clin Infect Dis. 2019;69(6):1071\u20138.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"12885_CR31","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"JA Salomon","year":"2015","unstructured":"Salomon JA, et al. Disability weights for the global burden of disease 2013 study. Lancet Glob Health. 2015;3(11):e712\u201323.","journal-title":"Lancet Global Health"},{"key":"12885_CR32","unstructured":"CDC. The pink book-Epidemiology and Prevention of Vaccine-Preventable Disease. [Cited. 2023 11\/12\/2023]. Available from: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/index.html."},{"issue":"9674","key":"12885_CR33","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(09)60317-2","volume":"373","author":"A Clark","year":"2009","unstructured":"Clark A, Sanderson C. Timing of children\u2019s vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet. 2009;373(9674):1543\u20139.","journal-title":"Lancet"},{"issue":"9","key":"12885_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40273-020-00930-6","volume":"38","author":"A Portnoy","year":"2020","unstructured":"Portnoy A, et al. Producing standardized Country-Level immunization delivery unit cost estimates. PharmacoEconomics. 2020;38(9):995\u20131005.","journal-title":"PharmacoEconomics"},{"key":"12885_CR35","unstructured":"UNICEF. Cost of Vaccinating a Child. 2020. [Cited 2023 27 December 2023]. Available from: https:\/\/www.unicef.org\/supply\/handling-fees."},{"issue":"7","key":"12885_CR36","doi-asserted-by":"publisher","first-page":"e68482","DOI":"10.1371\/journal.pone.0068482","volume":"8","author":"J Jiang","year":"2013","unstructured":"Jiang J, et al. Childhood intussusception: a literature review. PLoS ONE. 2013;8(7):e68482.","journal-title":"PLoS ONE"},{"issue":"1","key":"12885_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s12889-020-08595-8","volume":"20","author":"R Baral","year":"2020","unstructured":"Baral R, et al. Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates. BMC Public Health. 2020;20(1):619.","journal-title":"BMC Public Health"},{"issue":"3","key":"12885_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1287\/ited.1080.0013","volume":"8","author":"R Davis","year":"2008","unstructured":"Davis R. Teaching Note\u2014Teaching project simulation in excel using PERT-Beta distributions. INFORMS Trans Educ. 2008;8(3):139\u201348.","journal-title":"INFORMS Trans Educ"},{"key":"12885_CR39","unstructured":"Gavi. Eligiblity and Transition policy, Version 4.0. 2023. [Cited 2023 12\/23\/2023]. Available from: https:\/\/www.gavi.org\/types-support\/sustainability\/eligibility."},{"issue":"8","key":"12885_CR40","doi-asserted-by":"publisher","first-page":"e0001328","DOI":"10.1371\/journal.pgph.0001328","volume":"3","author":"R Owusu","year":"2023","unstructured":"Owusu R, et al. Rotavirus vaccine product switch in Ghana: an assessment of service delivery costs, switching costs, and cost-effectiveness. PLOS Glob Public Health. 2023;3(8):e0001328.","journal-title":"PLOS Glob Public Health"},{"issue":"4","key":"12885_CR41","doi-asserted-by":"publisher","first-page":"p1316","DOI":"10.1093\/ije\/dyz028","volume":"48","author":"AD Clark","year":"2019","unstructured":"Clark AD, et al. Update on the global epidemiology of intussusception: a systematic review of incidence rates, age distributions and case-fatality ratios among children aged <5 years,before the introduction of rotavirus vaccination. Int J Epidemiol. 2019;48(4):p1316\u20131326.","journal-title":"Int J Epidemiol"},{"key":"12885_CR42","doi-asserted-by":"crossref","unstructured":"Anderson JDt, et al. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria. PLoS ONE. 2020;15(5):e0232941.","DOI":"10.1371\/journal.pone.0232941"},{"issue":"6","key":"12885_CR43","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, et al. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342.","journal-title":"Lancet Glob Health"},{"issue":"49","key":"12885_CR44","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1016\/j.vaccine.2018.10.068","volume":"36","author":"C Pecenka","year":"2018","unstructured":"Pecenka C, et al. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines. Vaccine. 2018;36(49):7472\u20138.","journal-title":"Vaccine"},{"issue":"11","key":"12885_CR45","doi-asserted-by":"publisher","first-page":"e0187446","DOI":"10.1371\/journal.pone.0187446","volume":"12","author":"J Rose","year":"2017","unstructured":"Rose J, et al. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis. PLoS ONE. 2017;12(11):e0187446.","journal-title":"PLoS ONE"},{"key":"12885_CR46","doi-asserted-by":"crossref","unstructured":"Anwari P, et al. Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan, a test-negative case-control analysis. Lancet Global Health. 2024;12(9):e1517\u201325.","DOI":"10.1016\/S2214-109X(24)00237-7"},{"issue":"32","key":"12885_CR47","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1016\/j.vaccine.2015.06.064","volume":"33","author":"SL Pollard","year":"2015","unstructured":"Pollard SL, et al. Estimating the herd immunity effect of rotavirus vaccine. Vaccine. 2015;33(32):3795\u2013800.","journal-title":"Vaccine"},{"issue":"1","key":"12885_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3201\/eid2001.130019","volume":"20","author":"B de Freiesleben","year":"2014","unstructured":"de Freiesleben B, et al. Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan. Emerg Infect Dis. 2014;20(1):29\u201337.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"12885_CR49","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.vaccine.2021.01.051","volume":"39","author":"N Luangasanatip","year":"2021","unstructured":"Luangasanatip N, et al. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the National immunisation programme in Thailand. Vaccine. 2021;39(9):1402\u201314.","journal-title":"Vaccine"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12885-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12885-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12885-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:11:44Z","timestamp":1751602304000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12885-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12885"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12885-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4974322\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"25 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This evaluation received approval from the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (LSHTM) (ID: 29622, July 2023). The study does not involve human subjects or patient records; therefore, obtaining consent forms is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participants"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"926"}}